Cases selected for the AskAnzal weekly PMCPA insight newsletter
RCGP Overdiagnosis Group challenged a Pfizer/BMS Eliquis email promoting AF pulse checks at flu clinics for over-65s, alleging…
LEO discovered four cross-border transfers of value involving three UK patient organisations. Three 2019 payments were disclosed late…
A UK health professional complained that the Ajovy website entry pop-up lacked the generic name and black triangle.…
Pulse ad for Trixeo linked COPD exacerbations and death with a βTake action with Trixeoβ call-to-action, creating an…
PMCPA case AUTH/3728/1/23: complaint alleging promotion of Zeposia (ozanimod hydrochloride) against Bristol Myers Squibb. Outcome: no breach; matter…
Complaint alleged Roche funding wasnβt declared βfrom the outsetβ on patient organisation programme webpages/materials. Panel found complainant hadnβt…
An anonymous representative alleged pressure to promote Aldara off-licence and raised concerns about call-rate targets and a GP…
Novartisβ UK press release headline implied an overall survival benefit for Femara vs tamoxifen despite non-significant ITT results…
Allerganβs Botox monograph made comparative claims vs Dysport (and referenced Xeomin). Panel found several claims misleading/unsubstantiated and ruled…
A trust clinical director alleged a Pfizer rep was intimidating and applied inappropriate pressure when trying to access…
One real case. One key lesson. Every week β free.